Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
antagomiR-874-5p
- Development stage
- Preclinical
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intermuscular (injection), Local (hydrogel-mediated Release)
01
Overview
**antagomiR-874-5p** is a synthetic, chemically modified antisense oligonucleotide designed to specifically inhibit the activity of the microRNA miR-874-5p. It acts by binding to miR-874-5p and preventing its function in post-transcriptional gene regulation. In preclinical research, antagomiR-874-5p has been shown to improve myogenesis (formation of muscle tissue) in senescent satellite cells (SCs) by upregulating the expression of myogenin and promoting myotube formation[1][4]. Delivery via SC-targeting extracellular vesicles and injectable hydrogel systems has been explored as a novel therapeutic strategy for sarcopenia, an age-related muscle degeneration disorder[1][4]. The primary mechanism is direct inhibition of miR-874-5p, which modulates downstream targets and cellular differentiation. The agent is being evaluated in animal models and preclinical studies and is not yet approved for clinical use.
- Other names
- antagomiR-874-5pantagomiR874-5pantagomiR 874-5pant-874ant874ant 874
Beyond the preview
Go deeper on antagomiR-874-5p.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on antagomiR-874-5p.